Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents

References

• Maldonado-Valderrama J, Wilde P, Macierzanka A, et al. The role of bile salts in digestion. Adv Colloid Interface Sci. 2011;165:36–46.
   PubMed Web of Science ®Google Scholar
• Monte MJ, Marin JJG, Antelo A, et al. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol. 2009 Feb 21;15(7):804–816.
   PubMed Web of Science ®Google Scholar
• Pols TWH, Noriega LG, Nomura M, et al. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol. 2011;54:1263–1272.
   PubMed Web of Science ®Google Scholar
• Keitel V, Kubitz R, Häussinger D. Endocrine and paracrine role of bile acids. World J Gastroenterol. 2008;14:5620–5629.
   PubMed Web of Science ®Google Scholar
• Quinn M, DeMorrow SB. Bile in the brain? A role for bile acids in the central nervous system. J Cell Sci Ther. 2012;3:7.
   Google Scholar
• Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65:2461–2483.
   PubMed Web of Science ®Google Scholar
• Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res. 2007;24:1803–1823.
   PubMed Web of Science ®Google Scholar
• Sievänen E. Exploitation of bile acid transport systems in prodrug design. Molecules. 2007;12:1859–1889.
   PubMed Web of Science ®Google Scholar
• Balakrishnan A, Polli JE. Apical sodium dependent transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm. 2006;3:223–230.
   PubMed Web of Science ®Google Scholar
• Kramer W, Glombik H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr Med Chem. 2006;13:997–1016.
   PubMed Web of Science ®Google Scholar
• Madenci D, Egelhaaf SU. Self-assembly in aqueous bile salt solutions. J Colloid Interface Sci. 2010;15:109–115.
   Web of Science ®Google Scholar
• Calabresi M, Andreozzi P, La Mesa C. Supramolecular association and polymorphic behaviour in systems containing bile acid salts. Molecules. 2007;12:1731–1754.
   PubMed Web of Science ®Google Scholar
• Natalini B, Sardella R, Gioiello A, et al. Determination of bile salt critical micellization concentration on the road to drug discovery. J Pharm Biomed Anal. 2014;87:62–81.
   PubMed Web of Science ®Google Scholar
• Nonnappa MU Unlocking the potential of bile acids in synthesis, supramolecular/materials chemistry and nanoscience. Org Biomol Chem. 2008;6:657–669.
   PubMed Web of Science ®Google Scholar
• Pártay LB, Sega M, Jedlovszky P. Morphology of bile salt micelles as studied by computer simulation methods. Langmuir. 2007;23:12322–12328.
   PubMed Web of Science ®Google Scholar
• Faustino C, Serafim C, Ferreira I, et al. Solubilisation power of an amino acid-based gemini surfactant towards the hydrophobic drug amphotericin B. Colloids Surf A. 2014;480:426–432.
   Web of Science ®Google Scholar
• Serafim C, Ferreira I, Rijo P, et al. Lipoamino acid-based micelles as promising delivery vehicles for monomeric amphotericin B. Int J Pharm. 2015;497:23–35.
   PubMed Web of Science ®Google Scholar
• Galantini L, di Gregorio CM, Gubitosi M, et al. Bile salts and derivatives: rigid unconventional amphiphiles as dispersants, carriers and superstructure building blocks. Curr Opin Colloid Interface Sci. 2015;20:170–182.
   Web of Science ®Google Scholar
• di Gregorio CM, Pavel NV, Jover A, et al. pH sensitive tubules of a bile acid derivative: a tubule opening by release of wall leaves. Phys Chem Chem Phys. 2013;15:7560–7566.
   PubMed Web of Science ®Google Scholar
• Natalini B, Sardella R, Camaioni E, et al. Correlation between CMC and chromatographic index: simple and effective evaluation of the hydrophobic/hydrophilic balance of bile acids. Anal Bioanal Chem. 2007;388:1681–1688.
   PubMed Web of Science ®Google Scholar
• Roda A, Minutello A, Angellotti MA, et al. Bile acid structure-activity relationship: evaluation of bile acid lipophilicity using 1-octanol/water partition coefficient and reverse phase HPLC. J Lipid Res. 1990;31:1433–1443.
   PubMed Web of Science ®Google Scholar
• Stojancevic M, Pavlovic N, Golocorbin-Kon S, et al. Application of bile acids in drug formulation and delivery. Front Life Sci. 2013;7:112–122.
   Web of Science ®Google Scholar
• Garidel P, Hildebrand A, Knauf K, et al. Membranolytic activity of bile salts: influence of biological membrane properties and composition. Molecules. 2007;12:2292–2326.
   PubMed Web of Science ®Google Scholar
• Moghimipour E, Ameri A, Handali S. Absorption-enhancing effects of bile salts. Molecules. 2015;20:14451–14473.
   PubMed Web of Science ®Google Scholar
• Patra D, Ahmadieh D, Aridi R. Study on interaction of bile salts with curcumin and curcumin embedded in dipalmitoyl-sn-glycero-3-phosphocholine liposome. Colloids Surf B. 2013;110:296–304.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Maxwell KN, Sezgin E, et al. Bile acids modulate signalling by functional perturbation of plasma membrane domains. J Biol Chem. 2013;288:35660–35670.
   PubMed Web of Science ®Google Scholar
• Sharma R, Majer F, Peta VK, et al. Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A). Bioorg Med Chem. 2010;18:6886–6895.
   PubMed Web of Science ®Google Scholar
• Singh M, Singh A, Kundu S, et al. Deciphering the role of charge, hydration, and hydrophobicity for cytotoxic activities and membrane interactions of bile acid based facial amphiphiles. Biochim Biophys Acta. 2013;1828:1926–1937.
   PubMed Web of Science ®Google Scholar
• Randazzo RAS, Bucki R, Janmey PA, et al. A series of cationic sterol lipids with gene transfer and bactericidal activity. Bioorg Med Chem. 2009;17:3257–3265.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee J, Verma G, Aswal VK, et al. Tween 80-sodium deoxycholate mixed micelles: structural characterization and application in doxorubicin delivery. J Phys Chem B. 2010;114:16414–16421.
   PubMed Web of Science ®Google Scholar
• Tan Y, Qi J, Lu Y, et al. Lecithin in mixed micelles attenuates the cytotoxicity of bile salts in Caco-2 cells. Toxicol In Vitro. 2013;27:714–720.
   PubMed Web of Science ®Google Scholar
• Faustino CMC, Serafim CS, Ferreira IN, et al. Mixed micelle formation between an amino acid-based anionic gemini surfactant and bile salts. Ind Eng Chem Res. 2014;53:10112–10118.
   Web of Science ®Google Scholar
• Maswal M, Dar AA. Mixed micelles of sodium cholate and Brij30: their rheological behaviour and capability towards solubilisation and stabilization of rifampicin. Colloids Surf A. 2013;436:704–713.
   Web of Science ®Google Scholar
• Aburahma MH. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv. 2015;8:1–21.
   Google Scholar
• Pinto Reis C, Silva C, Martinho N, et al. Drug carriers for oral delivery of peptides and proteins: accomplishments and future perspectives. Ther Deliv. 2013;4:251–265.
   PubMedGoogle Scholar
• Pinto Reis C, Neufeld RJ, Ribeiro AJ, et al. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine. 2006;2:53–65.
   PubMed Web of Science ®Google Scholar
• Shukla A, Khatri K, Gupta PN, et al. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci. 2008;11:59–66.
   PubMed Web of Science ®Google Scholar
• Shukla A, Katare OP, Singh B, et al. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm. 2010;385:47–52.
   PubMed Web of Science ®Google Scholar
• Jain S, Harde H, Indulkar A, et al. Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Nanomedicine. 2014;10:431–440.
   PubMed Web of Science ®Google Scholar
• Damgé C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Del. 2008;5:1–24.
   PubMed Web of Science ®Google Scholar
• Niu M, Lu Y, Hovgaard L, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 2012;81:265–272.
   PubMed Web of Science ®Google Scholar
• Song KH, Chung SJ, Shim CK. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release. 2005;106:298–308.
   PubMed Web of Science ®Google Scholar
• Arzani G, Haeri A, Daeihamed M, et al. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomedicine. 2015;10:4797–4813.
   PubMed Web of Science ®Google Scholar
• Al-Mahallawi AM, Abdelbary AA, Aburahma MH. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam. Int J Pharm. 2015;485:329–340.
   PubMed Web of Science ®Google Scholar
• Pinto Reis C, Neufeld RJ, Ribeiro AJ, et al. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2:8–21.
   PubMed Web of Science ®Google Scholar
• Elnaggar YS. Multifaceted applications of bile salts in pharmacy: an emphasis on nanomedicine. Int J Nanomedicine. 2015;10:3955–3971.
   PubMed Web of Science ®Google Scholar
• Shi Z, Guo R, Li W, et al. Nanoparticles of deoxycholic acid, polyethylene glycol and folic acid-modified chitosan for targeted delivery of doxorubicin. J Mater Sci Mater Med. 2014;25:723–731.
   PubMed Web of Science ®Google Scholar
• Xiao K, Li Y, Lee J, et al. “OA02” peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res. 2012;72:2100–2110.
   PubMed Web of Science ®Google Scholar
• Le Dévédec F, Fuentealba D, Strandman S, et al. Aggregation behavior of pegylated bile acid derivatives. Langmuir. 2012;28:13431–13440.
   PubMed Web of Science ®Google Scholar
• Le Dévédec F, Strandman S, Hildgen P, et al. PEGylated bile acids for use in drug delivery systems: enhanced solubility and bioavailability of itraconazole. Mol Pharm. 2013;10:3057–3066.
   PubMed Web of Science ®Google Scholar
• Zhou H, Yu W, Guo X, et al. Synthesis and characterization of amphiphilic glycidol-chitosan-deoxycholic acid nanoparticles as a drug carrier for doxorubicin. Biomacromolecules. 2010;11:3480–3486.
   PubMed Web of Science ®Google Scholar
• Yan JK, Ma HL, Chen X, et al. Self-aggregated nanoparticles of carboxylic curdlan-deoxycholic acid conjugates as a carrier of doxorubicin. Int J Biol Macromol. 2015;72:333–340.
   PubMed Web of Science ®Google Scholar
• Li J, Huo M, Wang J, et al. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials. 2012;33:2310–2320.
   PubMed Web of Science ®Google Scholar
• Li J, Yin T, Wang L, et al. Biological evaluation of redox-sensitive micelles based on hyaluronic acid-deoxycholic acid conjugates for tumor-specific delivery of paclitaxel. Int J Pharm. 2015;483:38–48.
   PubMed Web of Science ®Google Scholar
• Chen W-Q, Wei H, Li S-L, et al. Fabrication of star-shaped, thermo-sensitive poly(N-isopropylacrylamide)–cholic acid–poly(ε-caprolactone) copolymers and their self-assembled micelles as drug carriers. Polymer. 2008;49:3965–3972.
   Web of Science ®Google Scholar
• Tang X, Cai S, Zhang R, et al. Paclitaxel-loaded nanoparticles of star-shaped cholic acid-core PLA-TPGS copolymer for breast cancer treatment. Nanoscale Res Lett. 2013;8:420.
   PubMed Web of Science ®Google Scholar
• Zeng X, Tao W, Mei L, et al. Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials. 2013;34:6058–6067.
   PubMed Web of Science ®Google Scholar
• Xiao K, Luo J, Fowler WL, et al. A self- assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials. 2009;30:6006–6016.
   PubMed Web of Science ®Google Scholar
• Li Y, Xiao K, Luo J, et al. A novel size-tunable nanocarrier system for targeted anticancer drug delivery. J Control Release. 2010;144:314–323.
   PubMed Web of Science ®Google Scholar
• Xiao K, Suby N, Li Y, et al. Telodendrimer-based nanocarriers for the treatment of ovarian cancer. Ther Deliv. 2013;4:1279–1292.
   PubMedGoogle Scholar
• Xiao K, Li Y, Luo J, et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32:3435–3446.
   PubMed Web of Science ®Google Scholar
• Li Y, Xiao K, Luo J, et al. Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. Biomaterials. 2011;32:6633–6645.
   PubMed Web of Science ®Google Scholar
• Li Y, Xiao W, Xiao K, et al. Well-defined, reversible boronate crosslinked nanocarriers for targeted drug delivery in response to acidic pH values and cis-diols. Angew Chem Int Ed Engl. 2012;51:2864–2869.
   PubMed Web of Science ®Google Scholar
• Huang W, Shi C, Shao Y, et al. The core-inversible micelles for hydrophilic drug delivery. Chem Commun (Camb). 2013;49:6674–6676.
   PubMed Web of Science ®Google Scholar
• Kramer W. Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery. Biol Chem 2011;392:77–94.
   PubMed Web of Science ®Google Scholar
• Tolle-Sander S, Lentz KA, Maeda DY, et al. Increased acyclovir oral bioavailability via a bile acid conjugate. Mol Pharm. 2004;1:40–48.
   PubMed Web of Science ®Google Scholar
• Rais R, Acharya C, Mackerell AD, et al. Structural determinants for transport across the intestinal bile acid transporter using C-24 bile acid conjugates. Mol Pharm. 2010;7:2240–2254
   PubMed Web of Science ®Google Scholar
• Lee S, Kim K, Kumar TS, et al. Synthesis and biological properties of insulin-deoxycholic acid chemical conjugates. Bioconjug Chem. 2005;16:615–620.
   PubMed Web of Science ®Google Scholar
• Chen D, Wang X, Chen L, et al. Novel liver-specific cholic acid-cytarabine conjugates with potent antitumor activities: synthesis and biological characterization. Acta Pharmacol Sin. 2011;32:664–672.
   PubMed Web of Science ®Google Scholar
• Wu D, Ji S, Wu Y, et al. Design, synthesis, and antitumor activity of bile acid-polyamine-nucleoside conjugates. Bioorg Med Chem Lett. 2007;17:2983–2986.
   PubMed Web of Science ®Google Scholar
• Qian S, Wu J-B, Wu X-C, et al. Synthesis and characterization of new liver targeting 5-fluorouracil-cholic acid conjugates. Arch Pharm (Weinheim). 2009;342:513–520.
   PubMed Web of Science ®Google Scholar
• Sreekanth V, Bansal S, Motiani RK, et al.. Design, synthesis, and mechanistic investigations of bile acid-tamoxifen conjugates for breast cancer therapy. Bioconjug Chem. 2013;24:1468–1484.
   PubMed Web of Science ®Google Scholar
• Monte MJ, Ballestero MR, Briz O, et al. Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. J Pharmacol Exp Ther. 2005;315:24–35.
   PubMed Web of Science ®Google Scholar
• Briz O, Macias RIR, Vallejo M, et al. Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors. Mol Pharm. 2003;63:742–750.
   PubMed Web of Science ®Google Scholar
• Anelli PL, Lattuada L, Lorusso V, et al. Conjugates of gadolinium complexes to bile acids as hepatocyte-directed contrast agents for magnetic resonance imaging. J Med Chem. 2004;47:3629–3641.
   PubMed Web of Science ®Google Scholar
• Janout V, Regen SL. Bioconjugate-based molecular umbrellas. Bioconjug Chem. 2009;20:183–192.
   PubMed Web of Science ®Google Scholar
• Janout V, Schell WA, Thévenin D, et al. Taming amphotericin B. Bioconjug Chem. 2015;26:2021–2024.
   PubMed Web of Science ®Google Scholar
• Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol Res. 2008;38:123–131.
   PubMed Web of Science ®Google Scholar
• Bernstein H, Bernstein C, Payne CM, et al. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol. 2009;15:3329–3340.
   PubMed Web of Science ®Google Scholar
• Kundu S, Kumar S, Bajaj A. Cross-talk between bile acids and gastrointestinal tract for progression and development of cancer and its therapeutic implications. IUBMB Life. 2015;67:514–523.
   PubMed Web of Science ®Google Scholar
• Horowitz NS, Hua J, Powell MA, et al. Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis. Gynecol Oncol. 2007;107:344–349.
   PubMed Web of Science ®Google Scholar
• Kim ND, Im E, Yoo YH, et al. Modulation of the cell cycle and induction of apoptosis in human cancer cells by synthetic bile acids. Curr Cancer Drug Targets. 2006;6:681–689.
   PubMed Web of Science ®Google Scholar
• Agarwal DS, Anantaraju HS, Sriram D, et al. Synthesis, characterization and biological evaluation of bile acid-aromatic/heteroaromatic amides linked via amino acids as anti-cancer agents. Steroids. 2016;107:87–97.
   PubMed Web of Science ®Google Scholar
• Brossard D, Lechevrel M, El Kihel L, et al. Synthesis and biological evaluation of bile carboxamide derivatives with pro-apoptotic effect on human colon adenocarcinoma cell lines. Eur J Med Chem. 2014;86:279–290.
   PubMed Web of Science ®Google Scholar
• Chong H-S, Song HA, Ma X, et al. Bile acid-based polyaminocarboxylate conjugates as targeted antitumor agents. Chem Commun (Camb). 2009 Jun 7;(21):3011–3013. doi: 10.1039/b823000e.
   Web of Science ®Google Scholar
• Vallejo M, Castro MA, Medarde M, et al. Novel bile acid derivatives (BANBs) with cytostatic activity obtained by conjugation of their side chain with nitrogenated bases. Biochem Pharmacol. 2007;73:1394–1404.
   PubMed Web of Science ®Google Scholar
• Xu Y, Luo Q, Lin T, et al. U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways. PLoS One. 2014;9:e113479.
   PubMed Web of Science ®Google Scholar
• Singh M, Bansal S, Kundu S, et al. Synthesis, structure-activity relationship, and mechanistic investigation of lithocholic acid amphiphiles for colon cancer therapy. Med Chem Commun. 2015;6:192–201.
   Web of Science ®Google Scholar
• Popadyuk II, Markov AV, Salomatina OV, et al. Synthesis and biological activity of novel deoxycholic acid derivatives. Bioorg Med Chem 2015;23:5022–5034.
   PubMed Web of Science ®Google Scholar
• Vang S, Longley K, Steer CJ, et al. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med. 2014;3:58–69.
   PubMedGoogle Scholar
• Amaral JD, Viana RJ, Ramalho RM, et al. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. 2009;50:1721–1734.
   PubMed Web of Science ®Google Scholar
• Palmela I, Correia L, Silva RFM, et al. Hydrophilic bile acid protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study. Front Neurosci. 2015;9:80.
   PubMed Web of Science ®Google Scholar
• Ramalho RM, Viana RJ, Low WC, et al. Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer’s disease. Trends Mol Med. 2008;14:54–62.
   PubMed Web of Science ®Google Scholar
• Lo AC, Callaerts-Vegh Z, Nunes AF, et al. Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. Neurobiol Dis. 2013;50:21–29.
   PubMed Web of Science ®Google Scholar
• Cortez LM, Campeau J, Norman G, et al. Bile acids reduce prion conversion, reduce neuronal loss, and prolong male survival in models of prion disease. J Virol. 2015;89:7660–7672.
   PubMed Web of Science ®Google Scholar
• Lai XZ, Feng Y, Pollard J, et al. Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc Chem Res. 2008;41:1233–1240.
   PubMed Web of Science ®Google Scholar
• Niemirowicz K, Surel U, Wilczewska AZ, et al. Bactericidal activity and biocompatibility of ceragenin-coated magnetic nanoparticles. J Nanobiotechnology 2015;13:32.
   PubMed Web of Science ®Google Scholar
• Epand RF, Pollard JE, Wright JO, et al. Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins. Antimicrob Agents Chemother. 2010;54:3708–3713.
   PubMed Web of Science ®Google Scholar
• Bansal S, Singh M, Kidwai S, et al. Bile acid amphiphiles with tunable head groups as highly selective antitubercular agents. Med Chem Commun. 2014;5:1761–1768.
   Web of Science ®Google Scholar
• Pore VS, Divse JM, Charolkar CR, et al. Design and synthesis of 11α-substituted bile acid derivatives as potential anti-tuberculosis agents. Bioorg Med Chem Lett. 2015;25:4185–4190.
   PubMed Web of Science ®Google Scholar